Artivion, Inc. (NYSE:AORT) Given Average Rating of “Moderate Buy” by Brokerages

Artivion, Inc. (NYSE:AORT) has received an average rating of “Moderate Buy” from the eight ratings firms that are covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation and seven have assigned a buy recommendation to the company. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $44.1667.

Several research firms recently commented on AORT. Citizens Jmp dropped their target price on Artivion from $53.00 to $48.00 and set a “market outperform” rating on the stock in a report on Friday, May 8th. Weiss Ratings lowered Artivion from a “hold (c-)” rating to a “sell (d+)” rating in a report on Monday, June 8th. Stifel Nicolaus set a $45.00 price objective on Artivion in a report on Monday, June 1st. Canaccord Genuity Group reaffirmed a “buy” rating and set a $36.00 price objective on shares of Artivion in a report on Tuesday. Finally, Needham & Company LLC dropped their price objective on Artivion from $58.00 to $44.00 and set a “buy” rating on the stock in a report on Friday, May 8th.

Insider Activity

In other Artivion news, SVP Andrew M. Green sold 44,001 shares of the firm’s stock in a transaction dated Thursday, June 11th. The stock was sold at an average price of $20.70, for a total transaction of $910,820.70. Following the transaction, the senior vice president owned 60,259 shares of the company’s stock, valued at approximately $1,247,361.30. This trade represents a 42.20% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 6.30% of the company’s stock.

Hedge Funds Weigh In On Artivion

Hedge funds have recently made changes to their positions in the company. Aster Capital Management DIFC Ltd grew its holdings in shares of Artivion by 402.3% during the third quarter. Aster Capital Management DIFC Ltd now owns 648 shares of the company’s stock worth $27,000 after purchasing an additional 519 shares during the last quarter. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Artivion during the third quarter worth about $27,000. Rockefeller Capital Management L.P. boosted its stake in shares of Artivion by 150.0% during the fourth quarter. Rockefeller Capital Management L.P. now owns 665 shares of the company’s stock worth $30,000 after buying an additional 399 shares during the period. Larson Financial Group LLC boosted its stake in shares of Artivion by 148.5% during the fourth quarter. Larson Financial Group LLC now owns 942 shares of the company’s stock worth $43,000 after buying an additional 563 shares during the period. Finally, USA Financial Formulas boosted its stake in shares of Artivion by 163.5% during the fourth quarter. USA Financial Formulas now owns 1,133 shares of the company’s stock worth $52,000 after buying an additional 703 shares during the period. Hedge funds and other institutional investors own 86.37% of the company’s stock.

Artivion Stock Performance

NYSE:AORT opened at $21.27 on Thursday. The firm has a market capitalization of $1.03 billion, a PE ratio of 88.63 and a beta of 1.26. The business’s fifty day moving average price is $28.16 and its 200 day moving average price is $36.44. The company has a debt-to-equity ratio of 0.48, a current ratio of 3.86 and a quick ratio of 2.80. Artivion has a 12 month low of $19.16 and a 12 month high of $48.25.

Artivion Company Profile

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.